» Abbott's Kaletra(R) Tablet Dosed Once-Daily Or Twice-Daily Demonstrated Similar Clinical Results Across Race And Gender Lines
Initial treatment regimens containing once-daily or twice-daily dosing of Abbott’s (NYSE: ABT) protease inhibitor Kaletra(R) (lopinavir/ritonavir) tablet provided similar results for controlling the…